Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677406 | 0.79 | GFER (0.45) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3678850 | 0.79 | RAB9A (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL3680258 | 0.79 | DYRK1A (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5847955 | 0.79 | CYP1A2 (0.49) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3677914 | 0.76 | CHRM2 (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL13508835 | 0.74 | DYRK1A (0.45) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3673790 | 0.71 | DYRK1A (0.44) | NPC1RAB9APOLB | |
| SCHEMBL12799099 | 0.70 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2ACP1 | |
| SCHEMBL4584286 | 0.70 | ALDH1A1 (0.56) | ALDH1A1NPC1RAB9ASMN1; SMN2ACP1 | |
| SCHEMBL1747940 | 0.69 | MEN1 (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404659-B1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2010-02-10 | — | — | EP | disclosed |
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| US-7144893-B2 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-11-04 | — | — | US | disclosed |
| EP-1404659-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004479-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | TXNRD3, TXNRD1, TXN | ALDH1A1 245/4885NPC1 3388/4885RAB9A 1821/4885 |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | TXNRD1, TXNRD3, TXNRD2 | ALDH1A1 556/4885NPC1 2747/4885RAB9A 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.